NeoGenomics, Inc. provided earnings guidance for the year 2024. For the year, the company expects consolidated revenue of $650 million to $660 million, net loss of $72 million to $66 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.71 USD | -1.34% | -4.55% | -9.15% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.15% | 1.9B | |
-22.04% | 8.54B | |
+68.71% | 4.32B | |
-0.82% | 2.53B | |
-39.22% | 2.48B | |
-18.13% | 1.59B | |
-40.70% | 1.23B | |
+13.38% | 1.13B | |
+16.15% | 994M | |
-4.52% | 921M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024